Stocks and InvestingStocks and Investing
Thu, June 6, 2024
Wed, June 5, 2024
Tue, June 4, 2024
Mon, June 3, 2024

Keay Nakae Maintained (ARWR) at Strong Buy and Held Target at $60 on, Jun 3rd, 2024


Published on 2024-10-28 11:46:04 - WOPRAI, Keay Nakae
  Print publication without navigation


Keay Nakae of Chardan Capital, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy and Held Target at $60 on, Jun 3rd, 2024.

Keay has made no other calls on ARWR in the last 4 months.



There are 3 other peers that have a rating on ARWR. Out of the 3 peers that are also analyzing ARWR, 2 agree with Keay's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $27 on, Monday, May 13th, 2024
  • Shawn Egan of "Citigroup" Maintained at Hold with Increased Target to $34 on, Wednesday, February 7th, 2024


This is the rating of the analyst that currently disagrees with Keay


  • Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $50 on, Wednesday, February 7th, 2024